, Tracking Stock Market Picks
Enter Symbol:
Intermune, Inc. (ITMN) [hlAlert]

up 96.49 %

Intermune, Inc. (ITMN) rated Buy with price target $32 by Stifel Nicolaus

Posted on: Monday,  Apr 9, 2012  8:25 AM ET by Stifel Nicolaus

Stifel Nicolaus rated Buy Intermune, Inc. (NASDAQ: ITMN) on 04/09/2012. Previously Stifel Nicolaus rated Buy Intermune, Inc. (NASDAQ: ITMN) on 12/20/2010.,
when the stock price was $37.61. Since then, Intermune, Inc. has gained 96.49% as of 09/26/2014's recent price of $73.90.
If you would have followed the previous Stifel Nicolaus's recommendation on ITMN, you would have gained 96.49% of your investment in 1376 days.

InterMune Pharmaceuticals Inc. develops and commercializes innovative products for the treatment of serious pulmonary and infectious diseases and congenital disorders. The company markets ACTIMMUNE for chronic granulomatous disease and osteopetrosis. The company has active development programs underway for the other disease areas, several of which are in mid-or advanced-stage human testing, known as clinical trials.

Stifel Nicolaus research focuses on all market caps, but is a leader in small- and mid-cap research. The department is staffed predominately with industry professionals from outside Wall Street. In fact, approximately 50% of its analysts have hands-on work experience in the industry that they research. Stifel Nicolaus believes industry experience, its opportunistic approach, and broad market cap coverage drive excess returns and its award-winning franchise.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
4/9/2012 8:25 AM Buy
14.07 32.00
as of 12/31/2012
1 Week down  -3.77 %
1 Month up  5.78 %
3 Months up  8.14 %
1 YTD down  -23.09 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
12/20/2010 8:25 AM Buy
37.61 56.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy